Exhibit 99.1


BIODEL REPORTS FOURTH QUARTER FISCAL YEAR 2013 FINANCIAL RESULTS

Conference Call and Audio Webcast Will be Held Today, December 18th, at 5:00 p.m. ET

DANBURY, Conn., December 18, 2013

(GLOBE NEWSWIRE) - Biodel Inc. (Nasdaq: BIOD) today reported financial results for the fourth fiscal quarter ended September 30, 2013.

Portfolio highlights since last fiscal quarter:

·

Executed long-term commercial supply agreement with BD (Becton, Dickinson and Company) for worldwide exclusive rights to the ultra-portable and proprietary Uniject™ device for the delivery of liquid glucagon to treat severe hypoglycemia.

·

Manufactured engineering batch of BIOD-961 glucagon formulation for the EZMix™ auto-reconstitution device in preparation for initiation of IND-enabling toxicology studies.

·

Presented preclinical glucagon formulation data at Diabetes Technology Meeting demonstrating commercially viable pharmacokinetic and pharmacodynamic profiles comparable to glucagon products marketed by Eli Lilly and Novo Nordisk.

·

Reported positive top-line data from Phase 2 clinical trial of ultra-rapid-acting insulin candidate BIOD-123 and requested meeting with FDA.

·

Improved stability of analog-based ultra-rapid-acting insulin formulations.

·

Initiated Phase 1 clinical trial of concentrated ultra-rapid-acting insulin candidate BIOD-531.

Dr. Errol De Souza, president and chief executive officer of Biodel, stated: “I am pleased with the progress we have made across our rapidly progressing portfolio of innovative therapies for the treatment of diabetes. We look forward to delivering on several key milestones in 2014 including reporting top-line data from the BIOD-531 Phase 1 trial in the next calendar quarter, identifying analog-based ultra-rapid-acting insulin candidates and initiating pivotal trials on our glucagon program in the second half of 2014.”

Fourth Quarter Financial Results

Biodel reported a net loss for the three months ended September 30, 2013 of $0.8 million, or $0.04 per share of common stock, compared to a net loss of $5.9 million, or $0.42 per share of common stock, for the same period in the prior year.

Research and development expenses were $2.9 million for the three months ended September 30, 2013, compared to $4.6 million for the same period in the prior year. The decrease in research




The following information was filed by Biodel Inc (BIOD) on Wednesday, December 18, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Biodel Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biodel Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account